Designed to target cyclin E-driven cancers, NKT3964 is an oral small molecule offering substantial promise for addressing a ...

We look forward to evaluating therapeutic activity in patients, focusing on Cyclin E overexpressing cancers, including ovarian and breast cancers.” Based on preclinical studies, APR-1051 is ...

It downregulates cyclin E and suppresses activating phosphorylation of CDK2 on Thr160. “We are pleased to share the discovery of NKT3447, a highly selective CDK2 inhibitor with unique properties ...

Zentalis Pharmaceuticals progresses with azenosertib in the DENALI trial for Cyclin E1-positive platinum-resistant ovarian cancer, aiming for FDA approval by 2026. Part 2a of the trial will determine ...

Zentalis also announced the publication of a paper in npj Precision Oncology, which highlights Cyclin E1/CDK2 activation as a potential biomarker for identifying patients most likely to benefit ...

CDK2 is a well-established vulnerability of multiple cancers, including tumors with increased expression of Cyclin E (CCNE) or the mutation/loss of the Retinoblastoma 1 gene (RB1). There are ...

(RTTNews) - Zentalis Pharmaceuticals, Inc. (ZNTL), Monday announced the first patient has been dosed in Part 2 of the Phase 2 DENALI clinical trial evaluating azenosertib in Cyclin E1+ platinum ...

Cyclin-dependent kinases are a type of serine/threonine kinase which are activated by cyclins to drive the progress of the cell cycle. The cell cycle is a comprised of 4 stages, which are tightly ...